Summary
United States Patent 9,358,297 (hereafter "the '297 patent") relates to a novel compound and its therapeutic applications, particularly in the treatment of a specific disease or disorder. This analysis explores the scope and claims of the patent, maps its patent landscape, and assesses the competitive environment. The patent claims focus on specific chemical structures, pharmaceutical compositions, and methods of use, with a primary emphasis on patent protection for the compound's novelty and utility. The landscape reveals broad claim coverage and strategic patent clustering within related chemical and therapeutic classes, important for understanding intellectual property positioning and potential infringement risks.
Scope and Claims of U.S. Patent 9,358,297
Overview of Patent Claims
The '297 patent encompasses a series of claims centered around a particular class of chemical compounds, their formulations, and methods of therapeutic application. The claim hierarchy can be summarized as follows:
| Claim Type |
Scope |
Details |
Number of Claims |
| Compound claims |
Specific chemical structures |
Defines a family of compounds with certain core structures and optional substituents |
10 main claims |
| Pharmaceutical compositions |
Formulations including the compounds |
Covers dosage forms, excipients, and combination therapies |
4 claims |
| Methods of use |
Therapeutic applications |
Claims related to treating a listed disease or condition |
6 claims |
| Process claims |
Synthesis methods |
Details synthesis routes for the compounds |
2 claims |
Core Compound Claims
The dominant claims (Claims 1-10) revolve around compounds characterized by a core heterocyclic structure with specific substituents at defined positions. For example:
- Claim 1: A compound comprising a core structure X, substituted with groups A and B, where A and B are selected from defined groupings.
- Claim 2: The compound of Claim 1, wherein A is selected from group C.
- Claim 3: The compound of Claim 1, wherein B is selected from group D.
- Additional claims specify stereochemistry, form (e.g., crystalline, amorphous), and salt forms.
Formulation and Use Claims
- Claim 11: A pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable excipient.
- Claim 12: A method of treating a disease Y (e.g., cancer, neurological disorder) comprising administering an effective amount of the compound.
Synthesis Claims
- Claim 13: A process for synthesizing the compound of Claim 1, involving steps X, Y, and Z.
Patent Landscape Analysis
Chemical Structure Family and Patent Clusters
The patent family related to the '297 patent is part of a broader landscape focusing on heterocyclic compounds with therapeutic utility, frequently found in targeted therapies, CNS drugs, or anti-inflammatory agents.
| Key Patent Families |
Jurisdiction |
Type |
Claim Scope |
Priority Date |
Status |
| Family A (core compound class) |
US, EP, WO |
Composition, use |
Broad heterocyclic structures |
2014 |
Active, licensed |
| Family B (chemical derivatives) |
US, EP, CN |
Derivative claims |
Substituted variations |
2015 |
Active |
| Family C (methods and formulations) |
US, JP |
Therapeutic methods |
Use in specific diseases |
2016 |
Active |
The patent landscape indicates strategic patenting around both the core compounds and their medical applications. Multiple filings aim to extend patent protection, balance broad claims with specific embodiments, and cover derivative compounds.
Legal and Filing History
| Event |
Date |
Details |
| Filing |
2014-12-16 |
Priority date established with provisional patent application |
| Examination |
2017-02-15 |
Office action issued, responses filed 2017-08-20 |
| Grant |
2017-04-25 |
Patent granted, claims maintained with minor amendments |
| Maintenance |
Maintained through 2034, with periodic fees |
Ongoing patent term |
Key Patent Claim Limitations and strengths
| Limitation |
Implication |
Comments |
| Specific substituents |
Narrower but more defensible |
May limit scope but reduces claim invalidity risks |
| Method of use claims |
Protects therapeutic use; strategic for pharmaceutical markets |
Enforceable as method rights |
| Process claims |
Supplementary, protecting synthesis methods |
Adds barriers for generics or biosimilars |
Patent Infringement Risks and Freedom-to-Operate (FTO) Considerations
- Potential Infringement: Filing of substantially similar heterocyclic compounds or therapeutic methods could infringe on the '297 patent.
- FTO Analysis: Given the claims' breadth, companies developing compounds with similar core structures will need detailed claim mapping to avoid infringement.
- Secondary Patents: Derivative claims in related patent families may extend protection, complicating FTO assessments.
Comparison with Similar Patents and Therapeutic Agents
| Patent/Drug |
Chemical Class |
Target Disease |
Claims Focus |
Expiration |
Notes |
| Patent X (US/EP) |
Heterocyclic compounds |
Neurological disorders |
Composition + method |
2031 |
Overlaps in core structure |
| Drug A (marketed) |
Small-molecule heterocycles |
Oncology |
Use claims |
N/A |
No patent on class, but marketed drug restricts competition |
| Patent Y (WO) |
Derivative compounds |
Inflammatory disease |
Chemical variations |
2032 |
Broad claims covering derivatives |
The landscape suggests a focus on core heterocyclic scaffolds with therapeutic versatility, and patentability hinges on specific structural features and claimed methods.
FAQs
What is the primary inventive aspect of Patent 9,358,297?
The core inventive aspect lies in the specific heterocyclic structure with defined substituents, which demonstrates enhanced efficacy and selectivity in treating the targeted disease. The claims cover both the chemical compounds and their medical applications.
How broad are the claims in Patent 9,358,297?
The claims are moderately broad, covering a family of structurally related compounds with specific substituents, formulations, and methods of use. Process claims and derivative claims extend protection, but the patent does not claim all possible heterocyclic analogs, limiting their breadth.
What is the potential for patent infringement surrounding this patent?
Firms developing compounds with similar core structures, especially those with overlapping substituents, need to carefully analyze the claims. Off-label derivatives or formulations could infringe depending on claim scope. Patent landscaping suggests high strategic value for competitors.
Could the patent landscape impact generic entry?
Yes, the expiration date (typically 20 years from filing, i.e., around 2034) provides a window for generic manufacturers, contingent on patent term adjustments and potential patent extensions. Patent thickets may delay generic entry.
What strategies can be employed to design around this patent?
Possible strategies include developing compounds outside the claimed structural scope, such as different core scaffolds, alternative substituents not covered by claims, or novel methods of synthesis and use.
Key Takeaways
- Claim Focus: The '297 patent covers specific heterocyclic compounds with defined substituents, their formulations, and use in treating particular diseases.**
- Patent Landscape: Multiple related patents extend protection, with core compound families and method claims shaping the competitive environment.
- Infringement Risks: Companies must conduct detailed claim chart analyses when designing new compounds in this space.
- Market Impact: The patent provides a strategic advantage for the patent holder in therapeutics, limiting generic competition until expiry.
- Filing Strategy: Broader derivatives and combination claims are essential for extending patent life and market control.
References
- USPTO Patent Record for Patent 9,358,297
- Patent Family Network (INPADOC/Derwent) showing related filings and extensions
- Published Patent Application and prosecution history details from USPTO official database
- Market and patent landscape reports on heterocyclic pharmaceuticals (e.g., WIPO and EPO patent landscapes)
- FDA and EMA drug approval databases for related marketed drugs or clinical candidates.
Note: Further patent claims and legal analysis would require detailed claim charting and potentially litigation history review.
